Brutalist Biotech

• Roche's Genentech sticks with Orionis in 2nd molecular glue deal worth $2B (55m)
• Accropeutics' TYK2/JAK1 inhibitor hits psoriasis endpoints in Chinese biotech's first phase 2 win (4h)
• PureTech shows durability of pulmonary fibrosis candidate deupirfenidone (19h)

• FDA sets stricter approval standards for COVID vaccines (20h)
• Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff (22h)
• Pfizer buys into PD-1/VEGF competition with 3SBio deal (23h)

• Genentech expands partnership with molecular glue biotech Orionis (2h)
• How PureTech’s lung fibrosis drug stacks up against the competition (2h)
• Altos Labs buys anti-aging startup Dorian Therapeutics (4h)

• RFK Claims Ignorance About HHS Research, Clinical Trial Cuts in Hearing (13m)
• Roche’s Genentech Fails to Win Adcomm Backing for Columvi Expansion (37m)
• Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan (2h)

Bio IT World

• Innovative Practices Winner: Chromatography Data Management (8h)
• Regeneron Acquires 23andMe for $256 Million (1d)
• Trends from the Trenches: Data, Discovery, Politics (6d)

• Risk scores accurately predicted heart attacks, study finds. With CT scans, they did even better (4h)
• Biden’s diagnosis highlights little-noticed rise in late-stage prostate cancers (4h)
• How photography helped heal a couple in the aftermath of cancer (4h)

• Valinor Discovery Launches to Simulate Drug Efficacy in Virtual Patients (1d)
• Dutch Startup CryoCloud Lands €2M to Automate Cryo-EM for Drug Discovery (1d)
• Kvantify Taps Gefion AI Supercomputer to Scale Quantum Chemistry Simulations for Drug Discovery (1d)

• Gene therapy for skin diseases: A field still finding its footing (5h)
• Seven lung cancer companies advancing new treatments in 2025 (1d)
• Will Europe become the new home for US researchers affected by policy shifts? (2d)

• Potential ALS Mitochondrial Target Identified with CRISPR, scRNA-seq (45m)
• Oligo Factory’s Low-Scale Synthesis Expands Access to Small, GMP-Ready Custom Nucleotides (1h)
• Rapid Method for Cell Density Measurement Could Help Predict Tumor Response to Treatment (14h)

• Sixteen Years With Leukemia Taught Me to Savor Life (39s)
• Finding Meaning After an Acute Myeloid Leukemia Diagnosis (16h)
• Early Arterial Thrombosis May Signal Future Cancer Risk (16h)

Contract Pharma*

• Regeneron in Deal to Acquire 23andMe for $256M (19h)
• Astoriom Expands Sample Stability Storage Services (20h)
• Fresenius Kabi Introduces Epinephrine Injection 30 mg per 30 mL Multi-Dose Vials (20h)

• Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia (1h)
• FDA approves Amneal’s self-administered migraine drug Brekiya (1d)
• MHRA approves guselkumab for Crohn’s disease and ulcerative colitis (2d)

• How a New PE-Backed RCM Company Plans to Fix the ‘Transactional Bowels of US Healthcare’ (9h)
• 3 Health Investors Share Their Most Controversial Industry Takes (9h)
• How a Tiny Federal Agency Supports Innovation & Competitiveness in the Scientific Community (9h)

• Editorial: Venture capital still likes cleantech (20h)
• A guide to navigating AI chemistry hype (20h)
• Federal policy changes spell turmoil for biopharma (22h)

The Pharma Letter*

• Juvenescence raises $76 million in first-close of Series B-1 round (44m)
• SparX teams with Mitsubishi Tanabe on novel ADC project (1h)
• PureTech’s deupirfenidone shows strong and durable efficacy (1h)

• CABINET Trial: Results (54m)
• CYTO-PV Trial Insights: Optimizing Hematocrit Targets and Thrombosis Prevention in Polycythemia Vera (55m)
• CABINET Trial: Study Design and Patient Population (1h)

• Fruergaard's exit leaves many questions: Speculation about cause, power struggle and US problems (19m)
• US health clinic Calibrate changes management (1h)
• Demant surpasses Novo Nordisk on list of Europe's best employers (2h)

• Autoimmune Disease, Transformed? (17h)
• Lose Your Crystalline Form and Go Amorphous (1d)
• Alzheimer's Update: Infectious Agents and Gamma-Secretase Too (5d)

• UK to start "world first" gonorrhoea vaccine programme (1h)
• Beckley's psychedelic med inches forward in depression (2h)
• UK trumpets £1bn investment plan from BioNTech (3h)

• BioNTech commits to up to £1 billion investment in the UK (1h)
• Weight loss with muscle preservation for novel small molecule (2h)
• Whitepaper: Transforming cardiac safety testing (3h)

Google News Biotech

• Lilly’s former small molecule head makes the leap to a rising biotech in obesity - Pharma Voice (26m)
• Kaida BioPharma Announces New Partnership with Northway Biotech for the Manufacturing of KAD101 - The Manila Times (39m)
• Northway Biotech Enters Manufacturing Agreement With Kaida BioPharma for Lead Oncology Program KAD101 - ACCESS Newswire (43m)